...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system.
【24h】

From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system.

机译：从个性化医学到个性化司法：司法系统中转化药物基因组学的承诺。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Enabled by pharmacogenomics (PGx), molecular imaging and other molecular biomarkers, personalized medicine (PM) promises to optimize therapy while minimizing side effects. It may also dramatically impact the justice system in ways we are only beginning to understand.Personalized medicine has already entered the curricula of well-regarded medical schools such as that of Johns Hopkins University (MD, USA) [1], but law schools offer no analog. Although clinical acceptance of PM has proved slow even with US FDA support [2,101], PM's legal ramifications are evident. Recently, for example, the FDA relabeled some drugs with companion PGx [2], such as warfarin withCYP2C9 and vitamin K epoxide reduct-ase complex 1 to reduce bleeding [3,4,101]. If PGx retrospectively reveals that the warfarin patient was at high risk and testing was not initially performed, litigation may follow. Indeed, some lawyers advertise on the internet for cases involving warfarin-related errors [102]. Consequently, PGx may become part of defensive medicine.
机译：通过药物基因组学（PGx），分子成像和其他分子生物标记物的支持，个性化医学（PM）有望优化治疗，同时最大程度地减少副作用。它也可能以我们刚刚开始理解的方式极大地影响司法系统。个性化医学已经进入了著名的医学院的课程，例如约翰·霍普金斯大学（美国马里兰州）[1]，但是法学院提供没有模拟。尽管即使在美国FDA的支持下，对PM的临床接受也证明很慢[2,101]，但PM的法律后果是显而易见的。例如，最近，FDA用PGx替代药物重新标记了某些药物，例如将华法林与CYP2C9和维生素K环氧还原酶复合物1结合使用以减少出血[3,4,101]。如果PGx回顾性地显示华法林患者处于高风险且最初未进行测试，则可能会提起诉讼。确实，一些律师在互联网上刊登广告，宣传涉及华法林相关错误的案件[102]。因此，PGx可能会成为防御医学的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号